Nicholas Yeo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Nicholas Yeo has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Amarinder Singh Thind
University of Wollongong
1 shared publication Antonia Shand
Department of Obstetrics & Gynaecology, The Royal Hospital for Women, Randwick, Australia
1 shared publication- Benjamin Genenger
School of Science and Molecular Horizons, Faculty of Science, Medicine and Health, University of Wollongong, Wollongong, NSW 2522, Australia
1 shared publication Benjamin Y. Kong
Department of Medical Oncology, Prince of Wales Hospital, Nelune Comprehensive Cancer Centre, Randwick, Australia
1 shared publication- Bruce Ashford
Department of Head and Neck Surgery Illawarra Shoalhaven Local Health District, Wollongong Hospital Wollongong New South Wales Australia
1 shared publication - Daniel Brungs
Illawarra Shoalhaven Local Health District, Wollongong, NSW 2500, Australia
1 shared publication
Latest Publications
- 22 January 2026
- Published by Wiley in Asia-Pacific Journal of Clinical Oncology
- Vol. 22 (4) , 501-507
Compassionate Access Drug Use for Solid Organ Malignancies in a Metropolitan Cancer Centre in Australia Between 2017 and 2024
Introduction: The Pharmaceutical Benefits Scheme (PBS) provides affordable access to cancer treatments in Australia. Not all cancer treatments are available on the PBS. Access to non‐PBS‐listed cancer treatments can occur through Compassionate Access Programs (CAPs). This retrospective review describes cancer treatments used via CAPs in a Metropolitan Cancer Centre in Australia. Methods: Patients with solid organ malignancies who had received drugs via compassionate access between 2017 and 2024 were identified via pharmacy and hospital medical records. Patients with hematological malignancies or who accessed drugs through out‐of‐pocket funding were excluded. CAPs were grouped into cost‐share/co‐pay and cost‐free programs. Results: Of 228 cases, 148 (64.9%) received the drug cost‐free, and 80 (35.1%) were on a cost‐share/co‐pay program. A total of 110 (48.2%) patients received the CAP drug as their first therapy. The median number of previous therapies before receiving CAP drug was 1 (range: 0–4). The median duration between diagnosis and use of CAP drug was 5.1 months (range: 0.2–96.0). The median and mean duration of CAP drug use were 5.2 and 10.3 months, respectively (range: 0.03–96.0). A total of 53 programs provided 40 drugs from 18 companies. Six drugs had both cost‐share/co‐pay and cost‐free programs. The drug with the most patients was pertuzumab ( n = 43), followed by nivolumab ( n = 27) and durvalumab ( n = 21). Fourteen patients accessing non‐oral drugs via cost‐share/co‐pay programs ultimately did not receive any free drugs. Conclusion: There is an increasing prevalence of novel drug use via CAPs across all types of cancers with promising impacts on patient outcomes.
- 22 January 2026
- Published by Wiley in Asia-Pacific Journal of Clinical Oncology
- Vol. 22 (4) , 501-507
Compassionate Access Drug Use for Solid Organ Malignancies in a Metropolitan Cancer Centre in Australia Between 2017 and 2024
Introduction: The Pharmaceutical Benefits Scheme (PBS) provides affordable access to cancer treatments in Australia. Not all cancer treatments are available on the PBS. Access to non‐PBS‐listed cancer treatments can occur through Compassionate Access Programs (CAPs). This retrospective review describes cancer treatments used via CAPs in a Metropolitan Cancer Centre in Australia. Methods: Patients with solid organ malignancies who had received drugs via compassionate access between 2017 and 2024 were identified via pharmacy and hospital medical records. Patients with hematological malignancies or who accessed drugs through out‐of‐pocket funding were excluded. CAPs were grouped into cost‐share/co‐pay and cost‐free programs. Results: Of 228 cases, 148 (64.9%) received the drug cost‐free, and 80 (35.1%) were on a cost‐share/co‐pay program. A total of 110 (48.2%) patients received the CAP drug as their first therapy. The median number of previous therapies before receiving CAP drug was 1 (range: 0–4). The median duration between diagnosis and use of CAP drug was 5.1 months (range: 0.2–96.0). The median and mean duration of CAP drug use were 5.2 and 10.3 months, respectively (range: 0.03–96.0). A total of 53 programs provided 40 drugs from 18 companies. Six drugs had both cost‐share/co‐pay and cost‐free programs. The drug with the most patients was pertuzumab ( n = 43), followed by nivolumab ( n = 27) and durvalumab ( n = 21). Fourteen patients accessing non‐oral drugs via cost‐share/co‐pay programs ultimately did not receive any free drugs. Conclusion: There is an increasing prevalence of novel drug use via CAPs across all types of cancers with promising impacts on patient outcomes.
- Open Access
- 1 January 2025
- Published by Wiley in Case Reports in Medicine
- Vol. 2025 (1)
Beating the Odds: A Successful Pregnancy in a Patient With ALK‐Rearranged Lung Cancer on Alectinib
The management of oncogene‐driven non–small cell lung cancer (NSCLC) during pregnancy presents unique challenges due to limited safety data on targeted therapies. Anaplastic lymphoma kinase (ALK)‐rearranged NSCLC is a rare but increasingly recognized entity in young women, including during pregnancy. Here, we report the case of a 37‐year‐old woman diagnosed with metastatic ALK‐rearranged NSCLC during her first pregnancy, who was commenced on alectinib. Following this, she had a successful second pregnancy whilst being treated with alectinib (withheld during weeks 6–10 of gestation to avoid the critical period of organogenesis). Both pregnancies resulted in healthy infants with no complications or evidence of developmental delays. This case highlights the importance of a multidisciplinary approach involving oncology, maternal‐fetal medicine, clinical genetics, obstetrics medicine, and obstetrics to balance maternal cancer control and fetal health. While preclinical studies of alectinib suggest teratogenic risks, this and other reported cases demonstrate its potential for safe use during pregnancy with careful planning. Pathological examination of the placenta in our case revealed no malignant cells, and maternal disease remained controlled. As targeted therapies extend survival in advanced NSCLC, more patients may contemplate pregnancy, emphasizing the need for robust evidence to guide treatment decisions. This case contributes to the growing body of evidence supporting the feasibility of managing pregnancy in patients with ALK‐rearranged NSCLC using targeted therapies like alectinib, while underscoring the importance of long‐term follow‐up for the exposed offspring.
- 1 January 2025
- Published by Wiley in Case Reports in Medicine
- Vol. 2025 (1)
Open AccessBeating the Odds: A Successful Pregnancy in a Patient With ALK‐Rearranged Lung Cancer on Alectinib
The management of oncogene‐driven non–small cell lung cancer (NSCLC) during pregnancy presents unique challenges due to limited safety data on targeted therapies. Anaplastic lymphoma kinase (ALK)‐rearranged NSCLC is a rare but increasingly recognized entity in young women, including during pregnancy. Here, we report the case of a 37‐year‐old woman diagnosed with metastatic ALK‐rearranged NSCLC during her first pregnancy, who was commenced on alectinib. Following this, she had a successful second pregnancy whilst being treated with alectinib (withheld during weeks 6–10 of gestation to avoid the critical period of organogenesis). Both pregnancies resulted in healthy infants with no complications or evidence of developmental delays. This case highlights the importance of a multidisciplinary approach involving oncology, maternal‐fetal medicine, clinical genetics, obstetrics medicine, and obstetrics to balance maternal cancer control and fetal health. While preclinical studies of alectinib suggest teratogenic risks, this and other reported cases demonstrate its potential for safe use during pregnancy with careful planning. Pathological examination of the placenta in our case revealed no malignant cells, and maternal disease remained controlled. As targeted therapies extend survival in advanced NSCLC, more patients may contemplate pregnancy, emphasizing the need for robust evidence to guide treatment decisions. This case contributes to the growing body of evidence supporting the feasibility of managing pregnancy in patients with ALK‐rearranged NSCLC using targeted therapies like alectinib, while underscoring the importance of long‐term follow‐up for the exposed offspring.
- Open Access
Sex as a Predictor of Response to Immunotherapy in Advanced Cutaneous Squamous Cell Carcinoma
Approximately 3–5% of patients with cutaneous squamous cell carcinoma (CSCC) develop advanced disease, accounting for roughly 1% of all cancer deaths in Australia. Immunotherapy has demonstrated significant clinical benefit in advanced CSCC in several key phase II studies; however, there are limited data for patients treated outside of clinical trials. This is particularly relevant in advanced CSCC, which is most often seen in elderly patients with significant comorbidities. Thus, we aim to describe our experience with immunotherapy in a cohort of patients with advanced CSCC in Australia. We retrospectively reviewed all advanced CSCC patients treated with immunotherapy within the Illawarra and Shoalhaven Local Health District. Among the 51 patients treated with immunotherapy, there was an objective response rate (ORR) of 53% and disease control rate (DCR) of 67%. Our most significant predictor of response was sex, with male patients more likely to have better responses compared to female patients (DCR 85% vs. 41%, p < 0.0001), as well as improved progression-free survival (HR 4.6, 95%CI 1.9–10.8, p = 0.0007) and overall survival (HR 3.0, 95%CI 1.3–7.1, p = 0.006). Differential expression analysis of 770 immune-related genes demonstrated an impaired CD8 T-cell response in female patients. Our observed ORR of 53% is similar to that described in current literature with durable responses seen in the majority of patients.
Open AccessSex as a Predictor of Response to Immunotherapy in Advanced Cutaneous Squamous Cell Carcinoma
Approximately 3–5% of patients with cutaneous squamous cell carcinoma (CSCC) develop advanced disease, accounting for roughly 1% of all cancer deaths in Australia. Immunotherapy has demonstrated significant clinical benefit in advanced CSCC in several key phase II studies; however, there are limited data for patients treated outside of clinical trials. This is particularly relevant in advanced CSCC, which is most often seen in elderly patients with significant comorbidities. Thus, we aim to describe our experience with immunotherapy in a cohort of patients with advanced CSCC in Australia. We retrospectively reviewed all advanced CSCC patients treated with immunotherapy within the Illawarra and Shoalhaven Local Health District. Among the 51 patients treated with immunotherapy, there was an objective response rate (ORR) of 53% and disease control rate (DCR) of 67%. Our most significant predictor of response was sex, with male patients more likely to have better responses compared to female patients (DCR 85% vs. 41%, p < 0.0001), as well as improved progression-free survival (HR 4.6, 95%CI 1.9–10.8, p = 0.0007) and overall survival (HR 3.0, 95%CI 1.3–7.1, p = 0.006). Differential expression analysis of 770 immune-related genes demonstrated an impaired CD8 T-cell response in female patients. Our observed ORR of 53% is similar to that described in current literature with durable responses seen in the majority of patients.